Customer Publication
Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model
Journal: Drug Delivery and Translational Research (2024)
Institution: Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, USA
Research Areas: Cancer Research
Cell Lines: MDA-MB-231ADR (triple negative adriamycin-resistant human breast cancer cell line)
Summary: Combination therapy with small interfering RNA (siRNA) and chemotherapeutic drug is proven to be effective in downregulating cancer resistance proteins, such as P-glycoprotein (P-gp). In this study, monoclonal antibody 2C5-modified dendrimer-based micelles were used to co-deliver siRNA and doxorubicin (DOX) to the tumor site in both male and female xenograft mouse model. We observed a 29% reduction of P-gp levels in both males and females with respect to the control. Using a HoloMonitor M4, the ability of the 2C5-modified formulation to affect the metastasis of highly aggressive triple negative breast cancer cell migration in (MDA-MB-231) was assessed by a wound healing, showing that treatment caused a clear decrease in cell migration.